CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

/C O R R E C T I O N -- Seismic Pharmaceuticals/

Phase 3IstaroximeNeutral
AI Analysis

Summary

Seismic Pharmaceuticals announced enrollment of the first patient in a global Phase 3 trial of Istaroxime for cardiogenic shock. This is a correction notice to a previously issued news release.

Clinical Trial Data

Phase

Phase 3

Importance:5/10
Sentiment:
0.00
Phase 3Clinical TrialPatient EnrollmentCorrection
Related Companies

Read the original article

Published by PR Newswire Biotech on September 10, 2026 7:42 PM

Read Original